Group items tagged

The PSNC on Friday said it has warned the DHSC about the "very serious impact" of the limited supply of certain antibiotics on pharmacies who are "having to chase stock, purchase without sight of any concession prices, and cope with increasing patient questions and abuse." With higher than usual number of cases of scarlet fever, caused by invasive Group A Streptococci (iGAS) infections, being reported in children across the country, supplies of antibiotics for Group A Strep treatment have seen a surge in demand, leading to limited supply at certain wholesalers and pharmacies. PSNC has urged the DHSC to adopt measures that could help to manage the current crisis, such as allowing pharmacists more freedom to change strengths or formulations without prescriber approval, outside of Serious Shortage Protocols. It has also raised concerns on the significant rise in wholesale prices of many oral antibiotics as a result of the surge in demand and the ongoing supply disruptions. PSNC also said they have received reports of some suppliers putting up their prices for any oral antibiotics they do have in stock.

The Competition and Markets Authority (CMA) has launched an investigation following 'rocketing prices of antibiotics in the wake of Strep A cases', Sky News reported on Wednesday (December 14). On Monday, the Department of Health issued a medicine supply notification for antibiotics for the treatment of Strep A. "Supplies of antibiotics for the treatment of Group A Strep have seen a surge in demand and may be temporarily in limited supply at certain wholesalers and pharmacies. Supplies are available with manufacturers, and deliveries into wholesalers and pharmacies are being expedited and are expected in the coming days" said DHSC. Sky quoted a spokesperson for the CMA as saying: "People have got real concerns about the price of antibiotics used to treat Strep A, and we want companies to be clear about their obligations under the law.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for antibiotics for the treatment of Group A Strep. "Supplies of antibiotics for the treatment of Group A Strep have seen a surge in demand and may be temporarily in limited supply at certain wholesalers and pharmacies," said DHSC. "Supplies are available with manufacturers, and deliveries into wholesalers and pharmacies are being expedited and are expected in the coming days." If the formulation of antibiotic prescribed is unavailable, DHSC has asked clinicians and local pharmacy teams to consider prescribing an alternative form or strength of the antibiotic where appropriate, ensuring the patient is not intolerant to any of the excipients in the alternative and is counselled on the appropriate dose (and volume) required.

he Healthcare Distribution Association (HDA) and the Pharmaceutical Services Negotiation Committee (PSNC) have urged the NHS England and the Department of Health and Social Care (DHSC) to issue urgent communications requesting that all those involved in medicines supply do not hoard, stockpile or over-prescribe Strep A antibiotics. In a statement HDA said that the sudden spike in demand for antibiotics used for the treatment of Strep A has meant that there is not enough of these medicines in the supply chain currently to meet this increased demand. As a result, wholesalers are working extremely hard with manufacturers to increase the supply of antibiotics. It added: "As regards pricing, the prices charged to pharmacies by HDA wholesale distributors will directly reflect the increase in prices wholesalers are having to pay for these medicines from manufacturers at the moment, in order to be able to continue supplying these medicines to pharmacies. This will be the case until supply and demand are more in sync."

The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the UK being deferred. Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.

The Department of Health and Social Care (DHSC) has allowed pharmacists to supply alternative penicillin to treat Strep A. It has issued Serious Shortage Protocols (SSPs) for three penicillin medicines. "The SSPs will help mitigate local supply issues of oral penicillin and allow pharmacists to supply alternative forms of the medicine if they do not have the specific formulation stated on the prescription," said DHSC. SSPs have been issued across the UK for 3 penicillin medicines on Thursday (December 15. "Issuing an SSP allows pharmacists to legally supply a specified alternative medicine, removing the need for the patient to return to the prescriber - which saves time in GP practices and inconvenience for patients." "Demand for penicillin has risen recently as it is used to treat strep A and scarlet fever, and the increased demand means that some pharmacists are experiencing temporary and localised supply issues and may not have the specific formulation listed on the prescription."

Product packaging affects the effectiveness of pharmaceuticals to a great extent. This is why pharmaceutical companies ensure they choose appropriate packaging for drug products. Drug packaging is not always an easy job. However, the tips in this article will help you select the proper pharmaceutical packaging for drug products without stress. What Does Pharmaceutical Packaging Entail? Pharmaceutical packaging involves using packaging containers with safety closures such as a lidding film to hold pharmaceutical products. This is done to keep them safe and effective. The most commonly used packaging materials in the pharmaceutical industry are metals, glass, and plastics. These materials are used for different reasons and different products. In short, a pharmacist considers several factors regarding a product and its target audience before choosing a packaging material for pharmaceutical formation. Why Appropriate Packaging Matters Many benefits come with appropriate pharmaceutical packaging. These benefits make it essential to package drug products in the best ways possible. When pharmaceutical items are properly packed, they can reach patients for a safe prescription. As a result, the drug stands a higher chance of achieving its prescription purpose. More so, properly packaged drug products are safer to consume and can be trusted.

The Pharmacists' Defence Association (PDA) has undertaken an additional survey of pharmacists employed in the NHS, before deciding to hold their first-ever ballot for industrial action. The PDA has more than 7,000 NHS-employed pharmacists in membership and the union is actively considering balloting those members regarding strike action. The association said: "The experience of some other unions has shown that the government's restrictive rules, designed to make it difficult for working people to lawfully take industrial action, means trade unions should test members' strength of feeling before balloting." "Trade unions are not only forced to rely upon postal ballots, but for lawful industrial action to be taken, the result must also meet three tests- at least 50% of eligible voters must vote; at least 40% of eligible voters must vote 'yes' and a majority of votes must be for 'yes'." The association is asking members in England, Northern Ireland and, Wales to show if their collective wish, insignificant enough strength, is for strike action. PDA has emailed the survey to all its members in the NHS in the three nations and will close on Tuesday 3 January.

The trade bodies and four largest pharmacy chains in England, have jointly written to the Secretary of State for Health, Steve Barclay, warning that the sector needs urgent investment for sustainability. The letter from AIMp, CCA, NPA, PSNC, Boots UK, Lloyds Pharmacy, Well, and Phoenix UK, warned that the 30 per cent real terms funding cuts that pharmacies have faced over the past seven years have left many businesses in a cashflow crisis. The letter said that the government is facing a choice over the future of the country's 11,000+ community pharmacies, with permanent closures likely and medicines supply at risk if no urgent action is taken. "If the funding situation is not addressed, the sector is likely to move rapidly towards many permanent closures of pharmacies." The organisations say that once these closures start, they will be hard to stop, as the sector is now so fragile other pharmacies would struggle to pick up the slack.

German biotechnology company BioNTech has signed a deal with the Department of Health and Social Care to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said. The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding the company's footprint in the UK, BioNTech said in a statement on Thursday (January 5). Under the agreement, the parties plan to utilise UK's clinical trial network, genomics and health data assets, aiming to enrol the first cancer patient in the second half of 2023, the company said.

The Company Chemist Association (CCA) highlighted its concerns around the recruitment of pharmacists into Primary Care Networks as well as the need for additional investment. Commenting on the Ipsos survey findings, the Malcolm Harrison, the Chief executive of the CCA said: "We welcome the findings of the Ipsos survey, confirming that patients value the quality of service and advice community pharmacies routinely provide. "We are very concerned however that this cancer detection pilot, and all other pharmacy services, are at risk if the NHS is not prepared to inject urgently needed funding into the sector." He stated that without substantial investment, "we will see the continued erosion of the service pharmacies can provide." In addition to the need for critical additional funding the association is also calling on the NHS to pause the recruitment of pharmacists into GP surgeries. He said: "Patients are suffering because the demand for pharmacists in England is now significantly greater than that which the existing workforce can deliver."

Nine in ten people surveyed by Ipsos on behalf on NHS positively rated the advice they received from their local pharmacies. The results from Ipsos found that the vast majority of patients (91%) who had used a community pharmacy in the previous year for advice about medicines, a health problem or injury, or what health service they should use said they received good advice. The research comes as more than 11,000 pharmacies in England can now access training to spot signs of cancer as part of a new drive to catch tumours earlier when they are easier to treat. Thorrun Govind, Chair of the Royal Pharmaceutical Society English Pharmacy Board, said: "Community pharmacists are working exceptionally hard to make sure that the public gets the right advice at the right time. This new data shows the public appreciate both the accessibility and quality of advice they receive from community pharmacists. "I am delighted that the Royal Pharmaceutical Society is working with the NHS to deliver professional development for community pharmacists to further enhance their clinical consultation skills.

Anglo-Swedish drugmaker AstraZeneca said on Monday (January 9) that it had struck a deal to buy US-based drug developer CinCor Pharma for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease. AstraZeneca aims to combine baxdrostat with its own Farxiga, a diabetes drug whose sales ballooned after it was also shown to benefit patients with heart failure and kidney disease. Farxiga, whose sales jumped by almost 50 per cent during the first nine months of 2022 to reach $3.2 billion, belongs to a highly competitive class of drugs that includes rivals such as Boehringer Ingelheim and Eli Lilly's Jardiance. AstraZeneca gets about a third of its revenue from cancer drugs, but its heart, kidney and diabetes medicines are its second most lucrative business by sales, generating roughly $6.9 billion of the drugmaker's total revenue of more than $33 billion in the first three quarters of 2022.

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

There are a lot of different beauty procedures that you can try in order to achieve healthy-looking skin. It's essential to consult with a dermatologist or other skin care professional to find out which procedures will work best for you, depending on your skin type and concerns. This article will briefly describe some of the different procedures that are available. Here are some contemporary beauty procedures to consider. 1. SKIN NEEDLING Skin needling, also known as micro-needling, is a minimally invasive procedure that can be used to improve the overall appearance of your skin. It involves using a device with fine needles to create tiny punctures on the skin's surface. Additionally, the effects of skin needling can last long after the initial treatment, making it a popular choice for those looking for a more lasting solution. This helps to stimulate collagen production and can reduce the appearance of wrinkles, fine lines, scarring, and other skin imperfections. Skin needling can be done independently or with other treatments such as radiofrequency therapy or chemical peels. It's important to note that skin needling should only be performed by a licensed professional. 2. RADIOFREQUENCY THERAPY If you're unhappy with the way your skin looks, it may be time to consider a radiofrequency therapy treatment. Radiofrequency therapy uses electromagnetic waves to heat up the deeper layers of your skin, stimulating collagen production and improving blood circulation. This can help to improve the appearance of wrinkles, fine lines, and sagging skin. Additionally, radiofrequency therapy can also help to improve the appearance of cellulite and stretch marks. It's a relatively safe and non-invasive procedure, and there is little to no downtime.

thx for sharing! i would like to use that

That is good option indeed but I guess with a complex training and suggestions u can temporally get rid of that( here for more info https://betterme.world/articles/does-cellulite-go-away/ ). While there is no guaranteed way to completely eliminate cellulite, there are various methods that can help reduce its appearance. Here are some options: Exercise: Regular exercise can help strengthen and tone muscles, reducing the appearance of cellulite. Healthy diet: Eating a healthy, balanced diet can help reduce the appearance of cellulite. Massage: Massaging the areas with cellulite may help improve circulation and reduce its appearance. Topical treatments: Creams and lotions containing caffeine, retinol, or antioxidants may help reduce the appearance of cellulite. Medical procedures: More invasive procedures such as laser therapy, radiofrequency treatments, and liposuction may also be options for reducing cellulite, but they can be expensive and may come with risks. It's important to remember that cellulite is a natural part of the body and many people have it, regardless of their weight or fitness level. While these methods may help reduce its appearance, it may not completely go away.

Community pharmacies will be able to deliver approximately 15 million blood pressure screenings by 2026, revealed the Company Chemists' Association (CCA)'s new research. This will also prevent 15,000 people from suffering heart attacks or strokes. CCA has called the Government to take up their offer and commission pharmacies as the first port of call for cardiovascular care. "Thousands of lives can be saved with ambitious commissioning and the investment to match," said CCA. There is an opportunity to use the expertise of community pharmacy to go further and provide the care these newly identified patients' need. To do this the sector needs funding and workforce. The association said: "Community pharmacy is under great financial pressure, suffering a real term funding cut of over 30% over 8 years. With funding, the sector can transform to deliver this critical need for patients. Whilst there are plans to train Independent Prescribers (IPs), there are no clear roles for them to use these skills. There is a need to accelerate training plans to allow pharmacists to deliver the service described here and play their part in CVD management."

The UK government's community diagnostic centre programme, which was first launch in July 2021, is helping cut waiting lists, and speed up diagnoses and treatments for NHS patients. As of November 2023, a total of 6.1 million vital checks have been carried out at community diagnostic centres (CDCs) across England, according to a joint statement released by the Department of Health and Social Care (DHSC) and NHS England. Under the £2.3 billion programme, 141 CDCs have been opened across the country in a variety of settings including shopping centres, university campuses and football stadiums, offering patients a wide range of diagnostic tests closer to home. The government has set a target to open 160 CDCs by March 2025, with many expected to open ahead of schedule.

More than 1.5 million courses of Pfizer's COVID-19 antiviral drug Paxlovid have expired unused in European countries by the end of November, the health analytics firm Airfinty has revealed. It is predicted that the figure could surge to 3.1 million, at a value of $2.2 billion (around £1.73 billion), by the end of Feb 2024. According to Airfinty analysis, Britain has the highest unused stock, with an estimated one million expired drug courses worth $700 million (over £550 million). With 2.2 million courses estimated to expire unused by the end of June 2024 due to the low prescription of the antiviral in the country, the total drug value wasted in the UK could reach $1.5 billion (£1.1 billion), the report added.

NHS West Yorkshire Integrated Care Board (ICB)'s decision to withdraw gluten free prescriptions for people with coeliac disease across Leeds and Calderdale has disappointed Coeliac UK. In a statement released on Thursday, the charity, which provides support and advice to those living with the disease, has raised "grave concerns" about the decision, warning that it will have a detrimental impact on the coeliac community. The policy is currently implemented across the ICB's other places including Bradford district and Craven, Kirklees and Wakefield district, preventing coeliac patients from accessing gluten free bread and flour mix on prescription. NHS West Yorkshire ICB wants to align its gluten free prescribing guidelines across its five places. But the charity is worried that the additional cost of gluten free staple products will poses a real challenge to maintaining the gluten-free diet, which is the only treatment for the condition.

The General Pharmaceutical Council (GPhC) and the Chief Pharmaceutical Officer for England have written a letter to pharmacy professionals thanking them for providing the best possible services to patients and the public, despite experiencing high and sustained demands and pressures. GPhC Chief Executive Duncan Rudkin and CPhO David Webb indicated that there will be further challenges over the coming weeks and months due to the ongoing industrial action, and staff shortages due to sickness or caring responsibilities. They expressed concerned that increased pressure will have a significant and potentially prolonged impact on pharmacy teams both personally and professionally. Acknowledging that pharmacy professionals may have to make some difficult decisions as they deal with the pressures they face, the leaders have urged those working in pharmacy to use "your professional judgement to assess and mitigate risk, and to deliver safe and effective care for your patients within your scope of practice."